Form 4: Director Sells Silence Therapeutics Shares

Richard Ian Griffiths, a director at Silence Therapeutics plc, reported the sale of American Depositary Shares (ADS) and ordinary shares across multiple transactions in late June and early July 2026.

Summary

• Richard Ian Griffiths, a director and 10% owner of Silence Therapeutics plc, has reported a series of transactions involving the sale of American Depositary Shares (ADS) and ordinary shares.
• These sales occurred between June 29, 2026, and July 6, 2026.
• The transactions involved a total of 1,234,214 American Depositary Shares (ADS) sold at prices ranging from $10.47 to $10.76.
• Correspondingly, 3,702,642 ordinary shares were disposed of as a result of these ADS sales.
• Following these transactions, Mr. Griffiths' beneficial ownership of ordinary shares has decreased.
• The sales were executed by Cream Capital Limited (CCL), of which Mr. Griffiths is a director and controlling shareholder, and also personally by Mr. Griffiths.
• Mr. Griffiths disclaims beneficial ownership of securities held by CCL except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant share sales by a director, which can be interpreted as a bearish signal.

Negatives

• Director Richard Ian Griffiths has sold a significant number of shares, reducing his direct and indirect beneficial ownership.
• The total number of ordinary shares disposed of through these transactions amounts to 3,702,642.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Industry Context

StockSavvy.ai notes that insider selling, particularly by directors, can sometimes signal a lack of confidence in future stock performance or a need for personal liquidity, though it can also be part of pre-planned diversification or financial planning strategies.

Related Party Transactions

• Sales were made by Cream Capital Limited (CCL), of which Mr. Griffiths is a director and controlling shareholder. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest.

Stakeholder Impact

• Shareholders may view the director's sales negatively, potentially impacting share price due to reduced insider confidence.
• Employees and other stakeholders may interpret the sales as a sign of potential future challenges for the company.

Key Dates

Recommendation

While insider selling can be a negative signal, this filing is a Form 4 reporting routine transactions. Without additional context on the company's financial health or strategic outlook, a 'hold' recommendation is prudent, advising investors to monitor further developments.

Keywords

Silence Therapeutics, SLN, Form 4, Insider Trading, Share Sale, Director Transaction, American Depositary Shares, Ordinary Shares, Beneficial Ownership